Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers

28 Aug 2019

Abstract excerpt

Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation. The heterogeneity of induced kinases prevents kinase targeting by a single kinase inhibitor and presents a major challenge to the treatment of therapeutically recalcitrant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31462705
DOI: 10.1038/s41388-019-0953-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancersPMID 31462705Read ↗

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerSemantic proximity Read ↗

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast CancerSemantic proximity Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

CDK7 in breast cancer: mechanisms of action and therapeutic potentialSemantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitorsSemantic proximity Read ↗

THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumoursSemantic proximity Read ↗

Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer TherapySemantic proximity Read ↗

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersSemantic proximity Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.